Merck reported solid third-quarter results, highlighting growth in key areas like diabetes and immunology, alongside significant milestones such as the FDA approval of KEYTRUDA for melanoma and its breakthrough designation for lung cancer. While the full-year guidance was narrowed due to currency fluctuations and decreased vaccine purchases, the strong performance in core segments and strategic focus on innovative therapies are likely to bolster investor confidence in the short term.

[1]